Details of Drug-Drug Interaction
| Drug General Information (ID: DDI6CVGTKM) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Pyrazinamide | Drug Info | Probenecid | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antitubercular Agents | Uricosuric Agents | |||||||
| Structure | |||||||||
| Mechanism of Pyrazinamide-Probenecid Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of uricosuric agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Pyrazinamide | Probenecid | |||||||
| Mechanism | Anti-uricosuric effects | Uricosuric effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Uricosuric agents | ||||||||
| Factor Description | The beneficial effects of uricosuric agents may be reduced, leading to an increased risk of hyperuricemia and gout. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution is advised when pyrazinamide is used concomitantly with uricosuric agents. Dosage adjustments as well as clinical and laboratory monitoring for altered uricosuric efficacy should be considered. Some authorities recommend avoiding concomitant use of pyrazinamide and probenecid (AU). | ||||||||